Buckley Mitchell S, Dzierba Amy L, Muir Justin, Gonzales Jeffrey P
1 Department of Pharmacy, Banner University Medical Center, Phoenix, AZ, USA.
2 Department of Pharmacy, New York-Presbyterian Hospital, NY, USA.
J Pharm Pract. 2019 Jun;32(3):347-360. doi: 10.1177/0897190019830504. Epub 2019 Feb 21.
Acute respiratory distress syndrome (ARDS) remains a common complication associated with significant negative outcomes in critically ill patients. Lung-protective mechanical ventilation strategies remain the cornerstone in the management of ARDS. Several therapeutic options are currently available including fluid management, neuromuscular blocking agents, prone positioning, extracorporeal membrane oxygenation, corticosteroids, and inhaled pulmonary vasodilating agents (prostacyclins and nitric oxide). Unfortunately, an evidence-based, standard-of-care approach in managing ARDS beyond lung-protective ventilation remains elusive, contributing to significant variability in clinical practice. Although the optimal therapeutic strategy for managing moderate to severe ARDS remains extremely controversial, therapies supported with more robust clinical evidence should be considered first. The purpose of this narrative review is to discuss the published clinical evidence for both pharmacologic and nonpharmacologic management strategies in adult patients with moderate to severe ARDS as well as to discuss practical considerations for implementation.
急性呼吸窘迫综合征(ARDS)仍然是危重症患者常见的并发症,常伴有严重的不良后果。肺保护性机械通气策略仍是ARDS治疗的基石。目前有多种治疗选择,包括液体管理、神经肌肉阻滞剂、俯卧位通气、体外膜肺氧合、皮质类固醇以及吸入性肺血管扩张剂(前列环素和一氧化氮)。遗憾的是,除肺保护性通气外,ARDS管理中基于证据的标准治疗方法仍难以确定,这导致临床实践存在显著差异。尽管中重度ARDS的最佳治疗策略仍极具争议,但应首先考虑有更充分临床证据支持的治疗方法。本叙述性综述的目的是讨论成人中重度ARDS患者药物和非药物管理策略的已发表临床证据,并讨论实施中的实际考虑因素。